Nurol GYO Valuation Multiples

Nurol GYO is valued at $54M as of September 2026, a 2.7x revenue multiple. In the last fiscal year, Nurol GYO revenue was $16M and Nurol GYO EBITDA was ($6M).

Nurol GYO Overview

About Nurol GYO

Nurol Gayrimenkul Yatirim Ortakligi AS is a real estate investment trust. Its main activities include creating the partnership portfolio, and changing it when necessary; distributing the risks involved; observing the stock exchange market.


Founded

1997

HQ

Turkey

Employees

51

Financials (Last FY)

Revenue: $16M
EBITDA: ($6M)

EV

$43M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nurol GYO Financials

Nurol GYO reported last fiscal year revenue of $16M and negative EBITDA of ($6M).

In the same fiscal year, Nurol GYO generated $7M in gross profit, ($6M) in EBITDA losses, and had net loss of ($10M).


Nurol GYO P&L

In the most recent fiscal year, Nurol GYO reported revenue of $16M and EBITDA of ($6M).

Nurol GYO is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of (39%), and net margin of (63%).

See analyst estimates for Nurol GYO
Last FY2025202620272028
Revenue$16M$16M
Gross Profit$7M$7M
Gross Margin48%48%
EBITDA($6M)($6M)
EBITDA Margin(39%)(39%)
EBIT Margin(5%)(5%)
Net Profit($10M)($10M)
Net Margin(63%)(63%)
Net Debt($596K)-

Financial data powered by Morningstar, Inc.

Nurol GYO Stock Performance

Nurol GYO has current market cap of $54M, and enterprise value of $43M.


Nurol GYO's stock price is $0.16.

Nurol GYO has an EPS (earnings per share) of $-0.03.

See more trading valuation data for Nurol GYO
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$43M$54M-2.0%---$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nurol GYO Valuation Multiples

Nurol GYO trades at 2.7x EV/Revenue multiple, and (7.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Nurol GYO

Nurol GYO Financial Valuation Multiples

As of September 22, 2026, Nurol GYO has market cap of $54M and EV of $43M.

Nurol GYO has a P/E ratio of (5.6x).

Last FY2025202620272028
EV/Revenue2.7x2.7x
EV/EBITDA(7.0x)(7.0x)
EV/EBIT(51.7x)(51.7x)
EV/Gross Profit5.7x5.7x
P/E(5.6x)(5.6x)
EV/FCF(50.5x)(50.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nurol GYO Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nurol GYO Margins & Growth Rates

In the most recent fiscal year, Nurol GYO reported gross margin of 48%, EBITDA margin of (39%), and net margin of (63%).

See estimated margins and future growth rates for Nurol GYO

Nurol GYO Margins

Last FY2025202720282029
Gross Margin48%48%
EBITDA Margin(39%)(39%)
EBIT Margin(5%)(5%)
Net Margin(63%)(63%)
FCF Margin(5%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Nurol GYO Operational KPIs

Nurol GYO's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Nurol GYO
Last FY2025202620272028
Revenue per Employee$0.3M-
Opex per Employee$0.2M-
S&M Expenses to Revenue18%18%
G&A Expenses to Revenue1%1%
Opex to Revenue53%53%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nurol GYO Competitors

Nurol GYO competitors include Deniz GYO, Liven, New Amsterdam Invest, Wikana, Brioschi, Copenhagen Capital, Mofast, FII AJ MALLS, EgnsInvest Ejd Tyskland and Manquehue.

Most Nurol GYO public comparables operate across Real Estate Development and Buildings & Property.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Deniz GYO$2M($4M)25.8x-(13.8x)-
Liven$57M$7M1.9x1.7x15.8x10.9x
New Amsterdam Invest$21M$10M7.0x-14.3x-
Wikana$41M$16M1.3x-3.4x-
Brioschi$21M$10M6.6x-14.2x-
Copenhagen Capital$9M-19.1x---
Mofast$22M$9M6.7x-16.0x-
FII AJ MALLS$702K-72.0x---

This data is available for Pro users. Sign up to see all Nurol GYO competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nurol GYO

When was Nurol GYO founded?Nurol GYO was founded in 1997.
Where is Nurol GYO headquartered?Nurol GYO is headquartered in Turkey.
How many employees does Nurol GYO have?As of today, Nurol GYO has over 51 employees.
Is Nurol GYO publicly listed?Yes, Nurol GYO is a public company listed on Borsa Istanbul.
What is the stock symbol of Nurol GYO?Nurol GYO trades under NUGYO ticker.
When did Nurol GYO go public?Nurol GYO went public in 1999.
Who are competitors of Nurol GYO?Nurol GYO main competitors include Deniz GYO, Liven, New Amsterdam Invest, Wikana, Brioschi, Copenhagen Capital, Mofast, FII AJ MALLS, EgnsInvest Ejd Tyskland, Manquehue.
What is the current market cap of Nurol GYO?Nurol GYO's current market cap is $54M.
What is the current revenue of Nurol GYO?Nurol GYO's last fiscal year revenue is $16M.
What is the current EV/Revenue multiple of Nurol GYO?Current revenue multiple of Nurol GYO is 2.7x.
Is Nurol GYO profitable?No, Nurol GYO is not profitable.
How many companies Nurol GYO has acquired to date?Nurol GYO hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nurol GYO has invested to date?Nurol GYO hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Nurol GYO

Lists including Nurol GYO

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial